BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...patent lawsuit, Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) is alleging that the sale of Ruzurgi amifampridine by Jacobus Pharmaceutical Co. Inc....
...GDC-0199 (Former compound #), venetoclax (Generic), Venclyxto (Other), Venclexta (Other) Endo International plc BioSpecifics Technologies Corp. Gemini Therapeutics Inc. Jacobus Pharmaceutical Co. Inc. Catalyst...
BioCentury | Sep 30, 2020
Product Development

Sept. 29 Quick Takes: Ironwood reduces headcount following Phase III miss; plus Sandoz, Catalyst, Myovant, Orphazyme, Synklino, WHO, BridgeBio, Kurma, Junshi, Arcutis, Genfit-LabCorp and GSK

...Pharmaceuticals Inc. (NASDAQ:CPRX) had filed that argued that FDA had illegally approved Ruzurgi amifampridine from Jacobus Pharmaceutical Co. Inc....
BioCentury | Feb 20, 2020
Politics, Policy & Law

Pharma execs speak out against 'misuse' of Orphan status as another old therapy sees a price hike

...launched at $375,000 per year, sparking outrage among patients, the public and politicians, given that Jacobus Pharmaceutical Co. Inc....
BioCentury | Feb 19, 2020
Politics, Policy & Law

FDA rebuts Catalyst charge that price drove Ruzurgi approval decision

...to price Firdapse at $375,000 per year provoked outrage among patients, the public and politicians. Jacobus Pharmaceutical Co. Inc....
...judgment against has not been determined. Steve Usdin, Washington Editor U.S. Food and Drug Administration (FDA) Catalyst Pharmaceuticals Inc. Jacobus Pharmaceutical Co. Inc. Firdapse drug...
BioCentury | Feb 13, 2020
Politics, Policy & Law

Catalyzing controversy: FDA emails challenge its claims that price plays no role in approvals

...which provides seven years of market exclusivity. Catalyst claims FDA illegally approved Ruzurgi amifampridine from Jacobus Pharmaceutical Co. Inc....
...the government’s request for summary judgment against has not been determined. Steve Usdin, Washington Editor Catalyst Pharmaceuticals Inc. Jacobus Pharmaceutical Co. Inc. U.S...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...relapsed or refractory diffuse large B-cell lymphoma who have received two or more prior therapies Jacobus Pharmaceutical Co. Inc....
BioCentury | Jun 12, 2019
Politics & Policy

Catalyst lawsuit challenges FDA's ability to bend the law to lower prices

...claims that FDA violated numerous agency regulations and laws when it approved Ruzurgi amifampridine from Jacobus Pharmaceutical Co. Inc....
...antitrust constraints prevent it from commenting on individual company pricing decisions. Steve Usdin, Washington Editor Catalyst Pharmaceuticals Inc. Jacobus Pharmaceutical Co. Inc. U.S...
BioCentury | May 7, 2019
Company News

Jacobus snags pediatric approval of rare autoimmune disease drug based on adult efficacy data

...Track and Orphan Drug status. FDA did not respond to inquiries in time for publication. Jacobus Pharmaceutical Co. Inc....
...on the price of Ruzurgi. Elizabeth S. Eaton, Staff Writer Firdapse, amifampridine phosphate (3,4-DAP, 3,4-diaminopyridine, Zenas) Catalyst Pharmaceuticals Inc. Jacobus Pharmaceutical Co. Inc. Lambert-Eaton...
BioCentury | Feb 29, 2016
Regulation

Competitive consequences

...gain ground in a race to market. Since Firdapse and 3,4-diaminopyridine ( 3,4-DAP ) from Jacobus Pharmaceutical Co. Inc....
...Minn. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), Coral Gables, Fla. Jacobus Pharmaceutical Co. Inc....
BioCentury | Sep 23, 2002
Company News

Immune Network Research Ltd., Jacobus Pharmaceuticals Co. Inc. deal

The companies signed a letter of intent for IMMFF to grant Jacobus an exclusive license to its data and IP for dapsone to treat Alzheimer's disease (AD) and other indications. IMMFF will receive a royalty...
Items per page:
1 - 10 of 10
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...patent lawsuit, Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) is alleging that the sale of Ruzurgi amifampridine by Jacobus Pharmaceutical Co. Inc....
...GDC-0199 (Former compound #), venetoclax (Generic), Venclyxto (Other), Venclexta (Other) Endo International plc BioSpecifics Technologies Corp. Gemini Therapeutics Inc. Jacobus Pharmaceutical Co. Inc. Catalyst...
BioCentury | Sep 30, 2020
Product Development

Sept. 29 Quick Takes: Ironwood reduces headcount following Phase III miss; plus Sandoz, Catalyst, Myovant, Orphazyme, Synklino, WHO, BridgeBio, Kurma, Junshi, Arcutis, Genfit-LabCorp and GSK

...Pharmaceuticals Inc. (NASDAQ:CPRX) had filed that argued that FDA had illegally approved Ruzurgi amifampridine from Jacobus Pharmaceutical Co. Inc....
BioCentury | Feb 20, 2020
Politics, Policy & Law

Pharma execs speak out against 'misuse' of Orphan status as another old therapy sees a price hike

...launched at $375,000 per year, sparking outrage among patients, the public and politicians, given that Jacobus Pharmaceutical Co. Inc....
BioCentury | Feb 19, 2020
Politics, Policy & Law

FDA rebuts Catalyst charge that price drove Ruzurgi approval decision

...to price Firdapse at $375,000 per year provoked outrage among patients, the public and politicians. Jacobus Pharmaceutical Co. Inc....
...judgment against has not been determined. Steve Usdin, Washington Editor U.S. Food and Drug Administration (FDA) Catalyst Pharmaceuticals Inc. Jacobus Pharmaceutical Co. Inc. Firdapse drug...
BioCentury | Feb 13, 2020
Politics, Policy & Law

Catalyzing controversy: FDA emails challenge its claims that price plays no role in approvals

...which provides seven years of market exclusivity. Catalyst claims FDA illegally approved Ruzurgi amifampridine from Jacobus Pharmaceutical Co. Inc....
...the government’s request for summary judgment against has not been determined. Steve Usdin, Washington Editor Catalyst Pharmaceuticals Inc. Jacobus Pharmaceutical Co. Inc. U.S...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...relapsed or refractory diffuse large B-cell lymphoma who have received two or more prior therapies Jacobus Pharmaceutical Co. Inc....
BioCentury | Jun 12, 2019
Politics & Policy

Catalyst lawsuit challenges FDA's ability to bend the law to lower prices

...claims that FDA violated numerous agency regulations and laws when it approved Ruzurgi amifampridine from Jacobus Pharmaceutical Co. Inc....
...antitrust constraints prevent it from commenting on individual company pricing decisions. Steve Usdin, Washington Editor Catalyst Pharmaceuticals Inc. Jacobus Pharmaceutical Co. Inc. U.S...
BioCentury | May 7, 2019
Company News

Jacobus snags pediatric approval of rare autoimmune disease drug based on adult efficacy data

...Track and Orphan Drug status. FDA did not respond to inquiries in time for publication. Jacobus Pharmaceutical Co. Inc....
...on the price of Ruzurgi. Elizabeth S. Eaton, Staff Writer Firdapse, amifampridine phosphate (3,4-DAP, 3,4-diaminopyridine, Zenas) Catalyst Pharmaceuticals Inc. Jacobus Pharmaceutical Co. Inc. Lambert-Eaton...
BioCentury | Feb 29, 2016
Regulation

Competitive consequences

...gain ground in a race to market. Since Firdapse and 3,4-diaminopyridine ( 3,4-DAP ) from Jacobus Pharmaceutical Co. Inc....
...Minn. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), Coral Gables, Fla. Jacobus Pharmaceutical Co. Inc....
BioCentury | Sep 23, 2002
Company News

Immune Network Research Ltd., Jacobus Pharmaceuticals Co. Inc. deal

The companies signed a letter of intent for IMMFF to grant Jacobus an exclusive license to its data and IP for dapsone to treat Alzheimer's disease (AD) and other indications. IMMFF will receive a royalty...
Items per page:
1 - 10 of 10